Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 13INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Leukemia, Myeloid, Acute 1Glioblastoma 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Spironolactone × Clear all
NCT07431216 2026-03-30

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression

Starlight Therapeutics Inc.

Phase 1/2 Not yet recruiting
68 enrolled
CNS

Glioblastoma

NCT03867682 2023-08-04

Venetoclax and Lintuzumab-Ac225 in AML Patients

Actinium Pharmaceuticals

Phase 1/2 Unknown
38 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡